This is an international site for Tasigna® (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional outside the US I am a US resident I am a patient outside the US
Print Text Size Glossary Summary of Product Characteristics Safety Information U.S. Residents

This site is intended for Healthcare Professionals outside the U.S.

TASIGNA is now indicated for patients newly diagnosed with Ph+

Is it possible to improve on imatinib?

TASIGNA has significantly more power to reduce progression vs imatinib to AP/BC than imatinib in patients with newly diagnosed Ph+ CML.

What outcomes can I expect in imatinib-resistant or -intolerant patients?

Achieve high overall survival with TASIGNA in heavily pretreated imatinib-resistant or -intolerant patients.

Can tolerability help patients maintain therapy?

TASIGNA has a favorable tolerability profile in newly diagnosed patients.

TASIGNA Interactive Game

ENESTnd 3-year publication

In adult patients with newly diagnosed Ph+ CML, more power to reduce disease progression vs imatinib1

Dosing TASIGNA — Tips to help your patients incorporate TASIGNA into their routines

References:
1. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; September 2012.
2. Cervantes C, Hughes T, Etienne G, et al. Nilotinib induces deeper molecular responses vs continued imatinib in patients with Ph+ chronic myeloid leukemia (CML) with detectable disease after ≥2 years on imatinib: ENESTcmr 12-month results [EHA abstract 0586]. Haematologica. 2012;97(suppl 1):239.
3. Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta. 2005;1754(1-2):3-13.